Completed OBSERVATIONAL NCT01635959

Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt (GERD Q NIS)

Sponsor: AstraZeneca

Conditions Patients With Upper Gastro-intestinal Symptoms

Updated 7 times since 2017 Last updated: Oct 2, 2014 Started: Jul 31, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01635959, this observational or N/A phase trial focuses on Patients With Upper Gastro-intestinal Symptoms and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Al Mansurah, Egypt , Al Menia, Egypt , Alex, Egypt , Asuit, Egypt , Aswān, Egypt , Banhā, Egypt , Cairo, Egypt , Domiaat, Egypt , Hurghada, Egypt , Ismailia, Egypt and 11 more locations